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Abstract
Background:  Patients with antipsychotic-induced weight gain (WG) regularly report on
unsuccessful dietary trials, which suggests strong biological weight gain drive that is extremely hard
to overcome with thoughts, such that behaviour doesn't change despite some intent to change. The
purpose of the present study was to assess cognitions specifically related to restrained eating in
severely overweight patients with schizophrenia treated with antipsychotic drugs.
Methods: Forty outpatients with schizophrenia and 40 controls without psychiatric disability were
included. Both groups were composed of one subgroup severely overweight (defined as a BMI >
28), and a comparison sample (BMI<28). The revised version of the Mizes Anorectic cognitive
questionnaire (MAC-R) was used in this cross-sectional case-control study.
Results: Gender was significantly related to eating disorders cognition, women scoring higher than
men. Patients with schizophrenia in general scored higher on the MAC-R total scale and on the
MAC-R subscale 2, the latter score representing rigid weight regulation and fear of weight gain.
When comparing the two groups of subjects with BMI < 28, it appeared that patients with
schizophrenia also scored higher on MAC-R total scale, the subscales 2 and 3, the latter subscale
3, indicating altered self control and self-esteem.
Conclusion: As is the case in weight gain of subjects without schizophrenia, the present results
suggest that the cognitive distortions, as assessed by the MAC-R, may play an important role in
weight gain also in patients with schizophrenia, and in weight gain associated with antipsychotic
pharmacotherapy. Particular attention to these processes may help to improve the management of
antipsychotic drugs induced weight gain.
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Background
Antipsychotic drugs (AP) induced weight gain (WG)
under chronic administration occurs in up to 50 % of
patients [1] and can lead to central or abdominal obesity
[2-5].
Antipsychotics vary in their propensity to cause weight
change with long-term treatment, and some of the atypi-
cal antipsychotics are among the drugs most frequently
associated with this side effect [1,6]. Besides the aesthetic
inconvenience, being overweight or obese increases the
risk of manifold somatic diseases[7], may impact impor-
tant aspects of health related quality of life [8], may affect
self-esteem, and impair adherence to long term antipsy-
chotic therapy [9,10].
WG under antipsychotic medications usually occurs
shortly after starting treatment [1,9]. Whereas some data
indicate that WG may reach a stable plateau after some
months [10,11], this has been contested [12]. Further-
more, WG seems to be dependent not only on the drug,
but also on patient related factors [4]. Whereas the best-
documented individual predictor of antipsychotic
induced WG has been shown to be a normal or low pre-
treatment weight [13,14], some controversy remains
about the link between good clinical response and WG
[1,9,15].
Different mechanisms have been hypothesized as mediat-
ing WG, e.g. an increase in global caloric intake due to an
appetite augmentation [16] and/or a satiety diminution
[17]. On the other hand, carbohydrate craving could not
be specifically related to antipsychotic induced WG [18].
Increased appetite and patient's eating behaviour seem to
be better predictors of WG than the physician's selection
of a specific agent [19].
If a better understanding of pharmacological and physio-
logical basis of AP induced WG is needed, other influ-
ences on the WG phenomenon also need to be
considered. Obesity can be considered as the result of
interactions between physiological, environmental and
behavioural factors, as well as cognitive attitudes and
beliefs towards food and body shape. In a time of wide
exposure to external risk factors for obesity (such as antip-
sychotic drugs), it may be particularly interesting to inves-
tigate personal characteristics associated with the
development of obesity.
Patients having gained weight under antipsychotics regu-
larly report on unsuccessful dietary trials as attempts to
counterregulate WG [20], which suggest strong cognitive
and behavioural participation to the WG phenomenon.
Whereas in general the fear of WG is likely to result in
numerous rigid and inaccurate food and weight related
attitudes in which the person struggles to keep control of
his weight and excessively anticipates the occurrence of
WG [21], this phenomenon may also be found in patients
with antipsychotic-associated WG. These attitudes have
been associated with restraint, which is defined as the
intention to restrict food intake consciously in order to
maintain body weight or to promote weight loss [22].
There might be several related behavioural strategies,
which may vary in their effectiveness in long-term food
reduction, and in their potential for producing distur-
bance of food intake regulation [5].
Furthermore, it has consistently been found, that
restrained eaters show a tendency to overeat under differ-
ent experimental conditions such as after food preload,
after alcohol consumption and in reaction to dysphoric
moods [22,23]. They were also found to increase con-
sumption of specific food in response to related cues [24].
Several studies have also shown a correlation between die-
tary restrained eating and binge eating [25], which is asso-
ciated with obesity in general [26,27] and also in AP
induced WG [20]. Moreover, binge eating has been sug-
gested to play a major role in WG persistence [28,29].
One can therefore hypothesize that the above-mentioned
attitudes partly explain interindividual WG liabilities in
patients treated with antipsychotic drugs. The purpose of
the present study was to assess cognitions that could be
specifically related to restrained eating in severely over-
weight atypical AP-treated patients with a diagnosis of
schizophrenia compared to 3 comparison groups.
Methods
Participants
The study sample consisted in 40 outpatients with schizo-
phrenia (DSM-IV) (19 female, mean age 33.8 ± 9.1) and
40 controls without psychiatric disability (21 female,
mean age 35.5 ± 10.79). Both groups were each composed
of two subgroups: one severely overweight subgroup
(defined as a BMI ≥ 28), and a comparison sample (BMI
< 28). All patients with schizophrenia were treated by
atypical AP for 8.3 ± 6.2 years (olanzapine, clozapine,
quetiapine and risperidone). Most patients were taking 1
or more comedications (alprazolam, atorvastatine,
clorazepate, citalopram, esomeprazole, flurazepam,
lorazepam, macrogolum, propranolol).
The recruitment procedure was as follows: the study was
systematically proposed during regular consultation to
outpatients with schizophrenia until reaching 20 patients
in each of the BMI subgroups. In total, the study was pro-
posed to 41 outpatients over a 6 month period. Only one
patient with obesity has refused to participate in the study.Clinical Practice and Epidemiology in Mental Health 2006, 2:29 http://www.cpementalhealth.com/content/2/1/29
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Controls consisted of clinic workers, informed through
local advertising. Mental disorders were excluded in non-
psychiatric control subjects throw absence of actual or
previous psychiatric treatment.
Informed consent was obtained from the participants
before inclusion in the study.
Design and Measures
The present survey was realized as a cross-sectional case-
control study. Subject's body weight and heights were
measured, and the BMI calculated as weight in kilograms
divided by the square of height in meters.
Psychiatric status was assessed through a chart review,
medical doctor referee and psychiatrist interview.
In order to assess the eating-related cognitive schemas,
especially dysfunctional cognitions, the revised version of
the Mizes Anorectic cognitive questionnaire (MAC-R)
[30] was used. Although the scale name refers to anorexia,
it is designed to assess cognitions for all eating disorders
[30,31]. It is a 24-item self-report questionnaire that
measures three dimensions of eating disorder cognitions:
strict weight regulation and fear of weight gain, self-con-
trol as the basis of self-esteem, and weight and eating
behaviour as the basis of approval. Each factor is 8 items
in length and contributes equally to the total score [30].
The items are rated using a 5- point Likert scale, with
higher scores indicating more dysfunctional cognitions.
The MAC-R subscales are highly correlated to the total
score and the total MAC-R score is highly correlated with
the MAC [30], as well as to other eating disorder question-
naires such as the Eating Disorders Inventory [32] and the
Restraint scale [33]. Both the MAC and the MAC-R have
been validated in clinical and non-clinical populations
[21,30], shown to assess an aspect of psychopathology
that is distinct from general psychological distress [34]
and finally have been found to be sensitive to the effect of
cognitive-behavioural therapy [30].
Data analyses
Descriptive statistics followed by Pearson's chi-square for
categorical data and ANOVA for parametric data were per-
formed for demographic variables and BMI.
Comparisons of MAC-R scores between groups were made
using two-way analysis of covariance (ANCOVA) with
weight status and psychiatric status (patients with schizo-
phrenia vs non psychiatric subjects) as fixed factors and
gender as a covariate (gender was used as a covariate as it
likely have an effect on cognitions related to eating behav-
iors) [35]. We set alpha level at .05. All analyses were com-
puted using the statistical software SPSS 14.0.
Results
Concerning the four groups, we examine skewness and
kurtosis statistics and their significance for MAC-R scores.
Results indicate that all distribution of scores are normal."
Characteristics of the samples
The characteristics of the 4 groups are shown in Table 1.
ANOVA and post-hoc comparisons revealed no differ-
ences with regard to age. Whereas no significant differ-
ences were found with regard to gender distribution, the
groups, as could easily be predicted, differed with regard
to the BMI. Post-hoc tests revealed no differences between
the two "BMI ≥ 28" groups and between the two "BMI <
28" groups, but significant differences between the "BMI
≥ 28" groups and the "BMI < 28" groups.
Cognitive distortions
Means and standard deviations of the MAC-R total score
and the subscales are shown in Table 2.
Total score
ANCOVA results indicated that the covariate, gender, was
significantly related to eating disorder cognitions (F(1,75)
= 8.50, p < .05), women (69.35 ± 16.10) scoring higher
than men (63.73 ± 14.91). There were significant main
effects of diagnosis (F(1,75) = 4.33, p < .05) and weight
group (F(1,75) = 24.06, p < .05), as well as an interaction
significant effect between diagnosis and weight (F(1,75) =
8.29, p < .05), after controlling for the effect of gender.
Schizophrenic patients with BMI < 28 scored higher than
controls in the same range of BMI (cf. Table 2).
Subscale 1 (Approval)
After controlling for effect of gender, a main effect
appeared for the weight factor (F (1;75) = 5.76; p < .05),
Table 1: Characteristics of the four groups
Schizophrenic patients (N = 40) Non-psychiatric subjects (N = 40) Statistical test
BMI < 28 BMI ≥ 28 BMI < 28 BMI ≥ 28
Age (M, SD) 31.7 ± 9.2 36.1 ± 8.9 33.9 ± 13.0 37.2 ± 8.1 F(3,76) = 1.18; NS
Women (%) 45 50 65 40 χ2(2) = 2.8; NS
BMI (M, SD) 23.6 ± 2.2 32.9 ± 6.1 21.1 ± 2.5 33.8 ± 4.9 F(3,76) = 46.07; p < .05Clinical Practice and Epidemiology in Mental Health 2006, 2:29 http://www.cpementalhealth.com/content/2/1/29
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but no significant effect for diagnosis and no significant
interaction between diagnosis and weight.
Subscale 2 (Weight regulation)
The analysis revealed significant main effects of weight (F
(1;75) = 20.89; p < .05] and diagnosis (F (1;75) = 4.39; p
< .05], as well as an interaction significant effect between
diagnosis and weight (F(1,75) = 4.85, p < .05), after con-
trolling for the effect of gender. Schizophrenic patients
with BMI < 28 scored higher than controls in the same
range of BMI (cf. Table 2).
Subscale 3 (Self control)
The covariate, gender, was significantly related to self-con-
trol dimension (F(1,75) = 12.58, p < .05), women (27.73
± 6.35) scoring higher than men (23.90 ± 6.81). After con-
trolling for the effect of gender, results indicated a signifi-
cant main effect of weight (F(1,75) = 9.65, p < .05), as well
as a significant interaction effect between diagnosis and
weight (F(1,75) = 6.60, p < .05). Similarly to previous
results for total score and weight regulation subscale,
schizophrenic patients with BMI < 28 scored higher than
controls in the same range of BMI (cf. Table 2).
Discussion
The aim of the present study was to assess anorectic cog-
nitions in overweight patients with schizophrenia treated
with antipsychotic drugs. Comparing these patients to
patients having schizophrenia with a BMI < 28, and with
non psychiatric control subjects, the following cognitive
patterns emerged, regardless of gender:
Patients with schizophrenia in general scored higher on
the MAC-R total scale and on the MAC-R subscale 2, the
latter score representing "rigid weight regulation and fear
of weight gain".
Subjects with BMI ≥ 28 as a whole scored higher on the
MAC-R total score and on each subscale.
When comparing the two groups of subjects with BMI <
28, it appeared that patients with schizophrenia also
scored higher on MAC-R scale and subscales 2 and 3, indi-
cating altered "weight regulation" and "self control".
As expected [35] the group of women as a whole scored
higher on the MAC-R total score and on the the subscale
3, indicating greater endorsement of self-control of weight
as the basis of self-esteem.
As, in contrast to the non psychiatric subjects, even
patients having schizophrenia with lower BMI show fear
of weight gain and rigid weight regulation as well as
altered self control, it raises the question whether these
anorectic cognitions are a pre-treatment trait or whether
they are induced by antipsychotic pharmacotherapy, since
the distortion in these cases (still) is not associated with
weight gain, by previous drug-induced weight gain or by a
more modest weight gain. Lack of data on the weight gain
history as well as the cross sectional design of the present
study do not allow this problem to be explored. A pro-
spective study would allow testing of the MAC-R scores as
a predictor of subsequent weight gains in patients with
presently low BMI.
Limitations of this study also included the choice of clin-
ical workers with probably different social and cultural
background than patients and the small size of the studied
samples.
A further rationalization of this observation could be the
existence of two subgroups of restrained eaters. One group
of patients having schizophrenia with anorectic cogni-
tions may be relatively successful in controlling weight,
whereas the second group includes the "unsuccessful diet-
ers".
In conclusion, the present study is, to our knowledge, the
first to describe anorectic cognitive distortions in patients
with schizophrenia treated with antipsychotic drugs. The
present findings are consistent with those of previous
studies with normal subjects and those studying patients
with eating disorders [34]. As is the case in weight gain of
non psychiatric subjects, the present results suggest that
the cognitive distortions, as assessed by the MAC-R, may
play an important role in weight gain also in patients with
schizophrenia, and in weight gain associated with antip-
sychotic pharmacotherapy. These eating related concerns
could contribute to maintenance of weight gain and thus
Table 2: MAC-R scores
Schizophrenic patients Non psychiatric subjects
BMI < 28 BMI ≥ 28 BMI < 28 BMI ≥ 28
Total score 66.2 ± 14.7 72.5 ± 14.4 53.4 ± 13.8 74.1 ± 11.5
Subscale 1: Approval 20.0 ± 6.2 21.3 ± 6.8 16.5 ± 4.6 20.6 ± 3.5
Subscale 2: Weight regulation 20.5 ± 6.6 24.1 ± 7.9 14.7 ± 5.7 24.0 ± 5.8
Subscale 3: Self-control 26.2 ± 5.8 27.2 ± 5.8 21.7 ± 7.6 28.2 ± 6.5Publish with BioMed Central    and   every 
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worsening obesity. It would be interesting to know
whether these subjects were experiencing binges and the
relationship between restriction and loss of control over
eating. Particular attention to these processes may help to
improve management of antipsychotic induced weight
gain.
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